Phenotypic variations in NF1-associated low grade astrocytomas: Possible role for increased mTOR activation in a subset

International Journal of Clinical and Experimental Pathology

Volumn 4, Issue 1, 2011, Pages 43-57

  Jentoft, Mark ^a   Giannini, Caterina ^a   Cen, Ling ^a   Scheithauer, Bernd W ^a   Hoesley, Bridget ^a   Sarkaria, Jann N ^a   Abell Aleff, Patrice C ^b   Rodriguez, Erika F ^a   Li, Ying ^a   Rodriguez, Fausto J ^a,c  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Astrocytoma; Glioma; Glioneuronal; Mtor; Neurofibromatosis; Pilocytic astrocytoma

Indexed keywords

DNA; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADOLESCENT; ADULT; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CELL ORGANELLE; CHILD; COMORBIDITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENETICS; GLIA; HUMAN; MALE; METABOLISM; MIDDLE AGED; NEUROFIBROMATOSIS; PATHOLOGY; PHENOTYPE; PRESCHOOL CHILD; ULTRASTRUCTURE;

ADOLESCENT; ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMORBIDITY; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 1; NEUROGLIA; ORGANELLES; PHENOTYPE; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 79955081038     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Rodriguez FJ, Perry A, Gutmann DH, O'Neill BP, Leonard J, Bryant S, Giannini C. Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol 2008; 67: 240-249.
2. Liberski PP, Kordek R. Ultrastructural pathology of glial brain tumors revisited: a review. Ultrastruct Pathol 1997; 21: 1-31.
3. Luse SA. An electron microscopic study of normal optic nerve and of an optic-nerve glioma. J Neurosurg 1961; 18: 466-478.
4. Soejima T, Kitamura K, Tomonaga M. [Electron microscopic observation of optic glioma--with special reference to the desmoplastic reaction (author's transl)]. No Shinkei Geka 1974; 2: 689-697.
5. Stern J, Jakobiec FA, Housepian EM. The architecture of optic nerve gliomas with and without neurofibromatosis. Arch Ophthalmol 1980; 98: 505-511.
6. Kim KY, Ju WK, Hegedus B, Gutmann DH, Ellisman MH. Ultrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic glioma. Neuroscience 170: 178-188.
7. Scheithauer BW, Bruner JM. The ultrastructural spectrum of astrocytic neoplasms. Ultrastruct Pathol 1987; 11: 535-581.
8. Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res 2005; 65: 2755-2760.
9. Gingras AC, Raught B, Sonenberg N. Control of translation by the target of rapamycin proteins. Prog Mol Subcell Biol 2001; 27: 143-174.
10. Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin-Kowalik J, Kotulska K, Kwiatkowski DJ. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 2004; 63: 1236-1242.
11. Rodriguez FJ, Giannini C, Asmann YW, Sharma MK, Perry A, Tibbetts KM, Jenkins RB, Scheithauer BW, Anant S, Jenkins S, Eberhart CG, Sarkaria JN, Gutmann DH. Gene expression profiling of NF-1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in aggressive subtypes. J Neuropathol Exp Neurol 2008; 67: 1194-1204.
12. Enna SJ, McCarson KE. The role of GABA in the mediation and perception of pain. Adv Pharmacol 2006; 54: 1-27.
13. Mikoshiba K, Fukuda M, Ibata K, Kabayama H, Mizutani A. Role of synaptotagmin, a Ca2+ and inositol polyphosphate binding protein, in neurotransmitter release and neurite outgrowth. Chem Phys Lipids 1999; 98: 59-67.
14. Mirza NR, Munro G. The role of GABA(A) receptor subtypes as analgesic targets. Drug News Perspect 23: 351-360.
15. Zhong L, Cherry T, Bies CE, Florence MA, Gerges NZ. Neurogranin enhances synaptic strength through its interaction with calmodulin. Embo J 2009; 28: 3027-3039.
16. Fedi M, Anne Mitchell L, Kalnins RM, Gutmann DH, Perry A, Newton M, Brodtmann A, Berkovic SF. Glioneuronal tumours in neurofibromatosis type 1: MRI-pathological study. J Clin Neurosci 2004; 11: 745-747.
17. Giannini C, Scheithauer BW, Lopes MB, Hirose T, Kros JM, VandenBerg SR. Immunophenotype of pleomorphic xanthoastrocytoma. Am J Surg Pathol 2002; 26: 479-485.
18. Lopes MB, Altermatt HJ, Scheithauer BW, Shepherd CW, VandenBerg SR. Immunohistochemical characterization of subependymal giant cell astrocytomas. Acta Neuropathol 1996; 91: 368-375.
19. Boer K, Troost D, Timmermans W, van Rijen PC, Spliet WG, Aronica E. Pi3K-mTOR signaling and AMOG expression in epilepsy-associated glioneuronal tumors. Brain Pathol 20: 234-244.
20. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006; 59: 490-498.
21. Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, Collins VP. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008; 68: 8673-8677.
22. Rodriguez EF, Scheithauer BW, Giannini C, Rynerason A, Cen L, Hoesley B, Gilmer-Flynn H, Sarkaria JN, Jenkins S, Long J, Rodriguez FJ. PI3K/AKT Pathway Alterations are Associated With Clinically Aggressive and Histologically Anaplastic Subsets of Pilocytic Astrocytoma. Acta Neuropathol 2010.
23. Zeng N, Liu L, McCabe MG, Jones DT, Ichimura K, Collins VP. Real-time quantitative polymerase chain reaction (qPCR) analysis with fluorescence resonance energy transfer (FRET) probes reveals differential expression of the four ERBB4 juxtamembrane region variants between medulloblastoma and pilocytic astrocytoma. Neuropathol Appl Neurobiol 2009; 35: 353-366.